Study finds methylphenidate may impact corneal cells in children with ADHD

News
Article

Methylphenidate is a central nervous system stimulant that is used to treat ADHD, a very common diagnosis in children in the US.

Frustrated child at table with teacher in classroom Image credit: AdobeStock/Photographee.eu

Image credit: AdobeStock/Photographee.eu

A study of the effects of methylphenidate in children with attention deficit hyperactivity disorder (ADHD) found lower corneal endothelial cell counts in those diagnosed with ADHD and undergoing treatment with methylphenidate compared with untreated children and a control group. The authors also reported that the ganglion cell layer (GCL) measurements were lower in the untreated children who were diagnosed with ADHD compared with those receiving methylphenidate and the control group.

First author Dilek Uzlu, MD, and colleagues from the Department of Ophthalmology, Medical Faculty, Karadeniz Technical University, Trabzon, Turkey, reported their results in International Ophthalmology.

Methylphenidate is a central nervous system stimulant that is used to treat ADHD, a very common diagnosis in children in the US.

This study focused on elucidating the ocular effects of methylphenidate on children diagnosed with ADHD and healthy controls. The participants were divided as follows: those diagnosed with ADHD and undergoing methylphenidate therapy (group 1), newly diagnosed untreated patients (group 2), and healthy, controls (group 3). The researchers evaluated the morphology and numbers of corneal endothelial cells, corneal thickness, choroidal thickness (CT), retinal thickness (RT), GCL, and retinal nerve fiber layer (RNFL) were evaluated.

Comparison of the 3 groups

Group 1 included 30 children (mean age, 10.53 ± 2.78 years) with ADHD treated with methylphenidate for a minimum of 1 year; group 2, 32 newly diagnosed untreated children (mean age, 9.21 ± 1.85 years); and group 3, 35 healthy children (mean age, 11.03 ± 3.01 years).

While the groups did not differ significantly (P > 0.05) in age, visual acuity level, or refractions, the researchers found that the endothelial cell counts and hexagonality values differed significantly between groups 1 and 2 (P = 0.041 and P = 0.031, respectively).

Other observations were that the GCL values differed between groups 1 and 2 and between groups 2 and 3 (P = 0.0001 and P = 0.02, respectively), but not between groups 1 and 3 (P = 0.551), the researchers reported.

The other parameters evaluated, ie, the central CT, central RT, and mean RNFL values did not differ significantly among the three groups (P > 0.05).

Uzlu and colleagues concluded, “Corneal endothelial counts were lower in the children diagnosed with ADHD and receiving methylphenidate therapy than in those not receiving treatment and the control group. In addition, GCL measurements were lower in the children diagnosed with ADHD and not using medication compared to those using methylphenidate and the control group.”

Reference
  1. Uzlu D, Bilginer SÇ, Yaşar Y, et al. An examination of the ocular effects of methylphenidate used in children and adolescents diagnosed with attention-deficit hyperactivity disorder. Int Ophthalmol. 2025;45. https://doi.org/10.1007/s10792-025-03471-z

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Setting the stage in LA: Neda Shamie, MD, on the 19th annual Controversies in Modern Eye Care meeting
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
© 2025 MJH Life Sciences

All rights reserved.